In summary, our multifaceted approach, incorporating new technologies such as scRNA-seq and ST as well as conventional cell line systems and animal models, highlights the importance of BCL2L1 expression in tumor cell survival as drug resistance emerges and cells acquire resistance to EGFR-TKI. The gene discussed is BCL2L1; the disease is neoplasm.